Skip to main content

Advertisement

Table 3 Antidiabetic activity of synthesized compounds

From: Synthesis, SAR and in vitro therapeutic potentials of thiazolidine-2,4-diones

Compound % inhibition
25 μg/ml 50 μg/ml 75 μg/ml 100 μg/ml IC50 (μg/ml)
1 22.65 35.79 55.52 88.68 54.35
2 17.89 42.62 59.78 74.67 47.51
3 29.45 47.98 60.83 95.79 43.45
4 31.26 40.65 63.93 92.61 43.63
5 18.26 47.61 49.24 96.72 56.64
6 33.56 49.45 50.78 97.15 37.35
7 24.72 35.71 64.87 97.15 56.09
8 20.79 39.54 40.89 93.17 56.89
9 24.73 53.78 68.34 89.37 41.67
10 29.34 43.98 63.36 98.14 47.49
11 18.49 47.87 59.74 89.71 52.69
12 27.77 53.23 62.27 79.43 27.63
13 25.74 43.89 56.76 92.72 48.45
14 21.78 48.82 72.54 93.92 50.80
15 32.59 51.78 66.98 81.30 22.35
16 27.52 43.73 57.27 85.23 40.92
17 23.67 48.56 65.46 93.17 48.48
18 18.64 45.85 65.11 95.98 56.39
19 29.33 47.77 58.34 90.86 40.01
20 34.73 45.98 68.34 88.45 31.62
21 21.98 47.28 70.56 74.76 38.65
Acarabose 37.35 53.45 73.25 88.57 21.44
  1. Compound numbers and their significant values are given in italic